Summary of findings 7. SSRIs compared to SNRIs for adults with panic disorder.
| SSRIs compared to SNRIs for adults with panic disorder | ||||||
| Patient or population: adults with panic disorder Settings: outpatient Intervention: SSRI Comparison: SNRI | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| SNRI | SSRI | |||||
| failure to respond Follow‐up: 12 weeks | 232 per 1000 | 223 per 1000 (174 to 285) | RR 0.96 (0.75 to 1.23) | 991 (2 studies) | ⊕⊕⊕⊕ high | |
| total number of dropouts Follow‐up: 2 weeks | 181 per 1000 | 201 per 1000 (134 to 298) | RR 1.11 (0.74 to 1.65) | 991 (2 studies) | ⊕⊕⊝⊝ low1,2 | |
| failure to remit Follow‐up: 12 weeks | 577 per 1000 | 606 per 1000 (525 to 698) | RR 1.05 (0.91 to 1.21) | 991 (2 studies) | ⊕⊕⊕⊕ high | |
| panic symptoms Follow‐up: 12 weeks | The mean panic symptoms in the intervention groups was 0.12 lower (0.33 lower to 0.10 higher) | 945 (2 studies) | ⊕⊕⊕⊕ high | |||
| number of dropouts due to adverse effects | 56 per 1000 | 104 per 1000 (27 to 393) | RR 1.86 (0.49 to 7.05) | 991 (2 studies) | ⊕⊕⊝⊝ low3,4 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Downgraded one point due to moderate heterogeneity (I2 = 53%) 2 Downgraded one point due to imprecision: 95% CI ranges from appreciable benefit with SSRIs to appreciable benefit with SNRIs 3 Downgraded one point due to substantial heterogeneity (I2 = 76%) 4 Downgraded one point due to serious imprecision: 95% CI ranges from no difference to benefit with SNRIs